{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2020"
                },
                "variant_string_id": "LRRK2 I2020T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in leucine - rich repeat kinase 2 (LRRK2) are a frequent cause of late - onset autosomal dominant Parkinson's disease (PD). Inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause PD and that inhibiting LRRK2 may be a treatment, thus defining the disease mechanism relevant to the functional assay.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Binding and enzymatic assays were used to study ATP affinity and kinase inhibitor sensitivity of the mutants. The assays aimed to investigate how the mutations affect LRRK2 function in the context of PD.",
                    "judgment": "Yes",
                    "reasoning": "The binding and enzymatic assays effectively model the disease pathogenesis as they study aspects of LRRK2 function (ATP affinity and inhibitor sensitivity) which are relevant to the proposed treatment of PD by LRRK2 inhibition.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Radiometric kinase activity assays were performed in duplicate. TR - FRET kinase activity assays were performed with either three or four replicates for each data point. Wild - type LRRK2 was used as a control.",
                    "judgment": "Yes",
                    "reasoning": "Both basic controls (wild - type LRRK2) and replicates were used in the assays, meeting the requirements for this step.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "Wild - type LRRK2 was used as a control, but no known pathogenic or benign variants other than the mutants themselves were mentioned as controls.",
                    "judgment": "No",
                    "reasoning": "Only wild - type was used as a control, and no known pathogenic/benign variants or variants reaching P/LP or B/LB criteria without PS3/BS3 evidence were used as controls.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 I2020T is rated as PS3_supporting because the disease mechanism was defined, the assays were applicable, basic controls and replicates were used, but no variant controls other than wild - type were utilized."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                    "position": "2019"
                },
                "variant_string_id": "LRRK2 G2019S"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in leucine - rich repeat kinase 2 (LRRK2) are a frequent cause of late - onset autosomal dominant Parkinson's disease (PD). Inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause PD and that inhibiting LRRK2 may be a treatment, thus defining the disease mechanism relevant to the functional assay.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Binding and enzymatic assays were used to study ATP affinity and kinase inhibitor sensitivity of the mutants. The assays aimed to investigate how the mutations affect LRRK2 function in the context of PD.",
                    "judgment": "Yes",
                    "reasoning": "The binding and enzymatic assays effectively model the disease pathogenesis as they study aspects of LRRK2 function (ATP affinity and inhibitor sensitivity) which are relevant to the proposed treatment of PD by LRRK2 inhibition.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Radiometric kinase activity assays were performed in duplicate. TR - FRET kinase activity assays were performed with either three or four replicates for each data point. Wild - type LRRK2 was used as a control.",
                    "judgment": "Yes",
                    "reasoning": "Both basic controls (wild - type LRRK2) and replicates were used in the assays, meeting the requirements for this step.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "Wild - type LRRK2 was used as a control, but no known pathogenic or benign variants other than the mutants themselves were mentioned as controls.",
                    "judgment": "No",
                    "reasoning": "Only wild - type was used as a control, and no known pathogenic/benign variants or variants reaching P/LP or B/LB criteria without PS3/BS3 evidence were used as controls.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_supporting because the disease mechanism was defined, the assays were applicable, basic controls and replicates were used, but no variant controls other than wild - type were utilized."
        }
    ]
}